Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $1.6 million.

  • Praxis Precision Medicines' Change in Accured Expenses fell 7084.26% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year decrease of 4179.5%. This contributed to the annual value of $16.1 million for FY2024, which is 28959.63% up from last year.
  • As of Q3 2025, Praxis Precision Medicines' Change in Accured Expenses stood at $1.6 million, which was down 7084.26% from $3.5 million recorded in Q2 2025.
  • Praxis Precision Medicines' 5-year Change in Accured Expenses high stood at $8.1 million for Q4 2024, and its period low was -$8.3 million during Q1 2025.
  • Moreover, its 4-year median value for Change in Accured Expenses was $374000.0 (2023), whereas its average is -$405333.3.
  • In the last 5 years, Praxis Precision Medicines' Change in Accured Expenses soared by 206711.23% in 2024 and then crashed by 126184.21% in 2025.
  • Praxis Precision Medicines' Change in Accured Expenses (Quarter) stood at -$2.0 million in 2022, then surged by 118.39% to $374000.0 in 2023, then skyrocketed by 2067.11% to $8.1 million in 2024, then plummeted by 80.53% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $3.5 million for Q2 2025, and -$8.3 million during Q1 2025.